Datopotamab Deruxtecan (Dato-DXd) clinical trials
4 indexed studies · 4 currently recruiting
- RecruitingPHASE2
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
This study is testing if a new combination of two drugs, Datopotamab Deruxtecan and Durvalumab, works better than Datopotamab Deruxtecan alone for a specific type of advanced triple-negative breast cancer. It focuses on patients whose cancer doesn't have a marker called PDL1.
For: Triple Negative Breast CancerUnited Kingdom - RecruitingPHASE3
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
This study looks into a new drug, Datopotamab Deruxtecan (Dato-DXd), for advanced lung cancer. It compares Dato-DXd to a standard treatment, Docetaxel, in patients whose cancer has responded to previous treatments and has a specific marker called TROP2.
For: Non-small Cell Lung Cancer (NSCLC)United States · Australia · Austria - RecruitingPHASE1, PHASE2
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
This study tests a new drug, AZD9574, alone and with other treatments, for people with advanced cancers. It aims to see how safe it is, how the body handles it, and if it helps shrink tumours.
For: Advanced Solid MalignanciesUnited States · Australia · Germany - RecruitingPHASE2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
This study looks at a new drug, Dato-DXd, by itself and with other treatments for different advanced cancers like those affecting the stomach, ovaries, and prostate. It checks if the treatment is safe and effective.
For: Endometrial Cancer · Gastric Cancer · Metastatic Castration-resistant Prostate CancerUnited States · Canada · China